In comparison to the RECIST 1.1 criteria, use of the mpMRI-based NacBI-RADS system for evaluating response to neoadjuvant chemotherapy (NAC) for breast cancer offered an 8 percent higher sensitivity and over 26 percent higher specificity.
In a new podcast episode, Manisha Bahl, MD, MPH, FSBI, discusses recently published guidelines on proliferative breast lesions with atypia and lobular carcinoma in situ (LCIS).
In a recent interview, Carolynn DeBenedectis, MD, discussed the utility of AI-enabled slab reconstruction for interpretation of digital breast tomosynthesis (DBT) and new research showing a 13 percent reduction in reading time.